3D·

The new Novo Nordisk 🙈

$KRYS (-1.76%)

However, earnings and profit growth are somewhat better than at Novo.

"Buy the dip"

Small additional purchase

04.08

Krystal Biotech

Bought x5 at €117.50

€587.50

12 Comments

K@TechNav

Sehr gute Margen! Wow

Gross Margin 93.37%
Operating Margin 42.26%
Pretax Margin 46.98%
Profit Margin 40.85%
EBITDA Margin 42.81%
EBIT Margin 42.26%
FCF Margin 36.00%

•

Tenbagger2024@Tenbagger2024

@TechNav
My dear,
That's what I'm saying.
Take a look at the EbiT margin at $CORT.
It increases by 10% every year.

••

Memo0606@Memo0606

just a little better ? 😂

••

Maximilian@Max095

Why the massive collapse today?

••

Tenbagger2024@Tenbagger2024

@Max095
It's in my first post.
One was below the estimates

•

Maximilian@Max095

@Tenbagger2024 Thank you. $BNTX could perhaps also be a good alternative. I have a lot in the pipeline for the future.

••

Tenbagger2024@Tenbagger2024

@Max095
I'm well supplied for now.
Going to other sectors.

•

Tenbagger2024@Tenbagger2024

@Max095 Good morning my dear,
$ALSTI I find it interesting, you can take a look.

•

Maximilian@Max095

@Tenbagger2024 Thank you :)

••

TomTurboInvest@TomTurboInvest

I've never even looked at it. What do they have in the pipeline? They are still quite small in terms of turnover.

••

Tenbagger2024@Tenbagger2024

@TomTurboInvest
Approvals in Japan and Europe are still pending. The growth rates are in double figures

•

MrStonkss@MrStonkss

What happens to sales and shares if or when other pipeline projects fail due to regulatory requirements or do not achieve the expected market penetration?

Krystal is currently heavily dependent on a single commercialized product, and a clinical or regulatory setback could wipe out most of the current growth in a very short time.

Is the current valuation with a P/E ratio of over 25 and a market capitalization of around USD 4 bn justified if the company does not yet have a broad, diversified product base or is the market simply paying for the hope of future blockbusters?

••